Antagonist Development Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Antagonist Development Program. Real-time updates on events, politics, business and more.

Liminal BioSciences Provides R&D Update

June 2, 2023

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead...

United Kingdom Bruce Pritchard Liminal Biosciences Inc Fairhaven Pharmaceuticals Inc World Health Organisation Agonist Development Program

Source: prnewswire.com

Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update

June 2, 2023

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)

United Kingdom Shrinal Inamdar Bruce Pritchard Kaitlin Gallagher Exchange Commission World Health Organisation

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Antagonist Development Program News Today

Liminal BioSciences Provides R&D Update

Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update

Explore More Categories